PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats

European Journal of Neuroscience

Volumn 21, Issue 4, 2005, Pages 1070-1076

  Rodefer, Joshua S ^a   Murphy, Emily R ^b   Baxter, Mark G ^c  

^a E11 SSH   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Attention; Executive functions; Frontal cortex; Learning; NMDA

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PAPAVERINE; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; BRAIN FUNCTION; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; CONTROLLED STUDY; DISCRIMINATION LEARNING; DISEASE ASSOCIATION; DRUG EFFECT; EXPERIMENTAL MODEL; FRONTAL LOBE; FUNCTIONAL DISEASE; LEARNING DISORDER; LIMBIC CORTEX; MALE; MEMORY DISORDER; NEOCORTEX; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RAT STRAIN; RECEPTOR BLOCKING; SCHIZOPHRENIA; TASK PERFORMANCE; TECHNIQUE; TISSUE STRUCTURE; WORKING MEMORY;

ANALYSIS OF VARIANCE; ANIMALS; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; DISCRIMINATION LEARNING; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; PAPAVERINE; PHENCYCLIDINE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, LONG-EVANS;

EID: 16244376475     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2005.03937.x     Document Type: Article

References (48)

1. Barense, M.D., Fox, M.T. & Baxter, M.G. (2002) Aged rats are impaired on an attentional set-shifting task sensitive to medial frontal cortex damage in young rats. Learn. Mem., 9, 191-201.
2. Birrell, J.M. & Brown, V.J. (2000) Medial frontal cortex mediates perceptual attentional set shifting in the rat. J. Neurosci., 20, 4320-4324.
3. Bradshaw, J.L. & Sheppard, D.M. (2000) The neurodevelopmental fronto-striatal disorders: evolutionary adaptiveness and anomalous lateralization. Brain. Lang., 73, 297-320.
4. Brooks, W.J., Weeks, A.C., Leboutillier, J.C. & Petit, T.L. (1997) Altered NMDA sensitivity and learning following chronic developmental NMDA antagonism. Physiol. Behav., 62, 955-962.
5. Brown, V.J. & Bowman, E.M. (2002) Rodent models of prefrontal cortical function. Trends Neurosci., 25, 340-343.
6. Brown, S.L., Haas, C.A., Koehler, M., Bodner, D.R. & Seftel, A.D. (1998) Hepatotoxicity related to intracavernous pharmacotherapy with papaverine. Urology, 59, 155-158.
7. Chen, K.C., Baxter, M.G. & Rodefer, J.S. (2004) Central blockade of muscarinic cholinergic receptors disrupts affective and attentional set-shifting. Eur. J. Neurosci., 20, 1081-1088.
8. Chutae, D.L., Villiger, J.W. & Kirton, N.F. (1981) Testing cyclic AMP mediation of memory: reversal of alpha-methyl-p-tyrosine-induced amnesia. Psychopharmacology, 74, 129-131.
9. Dias, R., Robbins, T.W. & Roberts, A.C. (1996) Dissociation in prefrontal cortex of affective and attentional shifts. Nature, 380, 69-72.
10. Fenton, W.S., Stover, E.L. & Insel, T.R. (2003) Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective. Psychopharmacology, 169, 365-366.
11. Fox, M.T., Barense, M.D. & Baxter, M.G. (2003) Perceptual attentional set-shifting is impaired in rats with neurotoxic lesions of posterior parietal cortex. J. Neurosci., 23, 676-681.
12. Fujii, D.E. & Wylie, A.M. (2003) Neurocognition and community outcome in schizophrenia: long-term predictive validity. Schizophr. Res., 59, 219-223.
13. Fujishige, K., Kotera, J. & Omori, K. (1999) Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rate PDE10A. Eur. J. Biochem., 266, 1118-1127.
14. Goto, K., Mochizuki, H., Hattori, T., Nakamura, N. & Mizuno, Y. (1997) Neurotoxic effects of papaverine, tetrahydropapaverine and dimethoxyphenylethylamine on dopaminergic neurons in ventral mesencephalic-striatal co-culture. Brain Res., 754, 260-268.
15. Graybiel, A.M. (2000) The basal ganglia. Curr. Biol., 10, R509-R511.
16. Green, M.F. (1996) What are the functional consequences of neurocognitive deficits of schizophrenia? Am. J. Psychiatry, 153, 321-330.
17. Green, M.F., Kern, R.S., Braff, D.L. & Mintz, J. (2000) Neurocognitive deficits and functional outcome in schizophrenia; Are we measuring the 'right stuff?'. Schizophr. Bull., 26, 119-136.
18. Harvey, P.D., Geyer, M.A., Robbins, T.W. & Krystal, J.H. (2003) Cognition in schizophrenia: from basic science to clinical treatment. Psychopharmacology, 169, 213-214.
19. Hori, T., Subramaniam, S., Srivastava, L.K. & Quirion, R. (2000) Behavioral and neurochemical alterations following repeated phencyclidine administration in rats with neonatal ventral hippocampal lesions. Neuropharmacology, 39, 2478-2491.
20. Hyman, S.E. & Fenton, W.S. (2003) What are the right targets for psychopharmacology? Science, 299, 350-351.
21. Jardemark, K.E., Ninan, I., Liang, X. & Wang, R.Y. (2003) Protein kinase C is involved in clozapine's facilitation of N-methyl-D-aspartate- and electrically evoked responses in pyramidal cells of the medial prefrontal cortex. Neuroscience, 118, 501-512.
22. Jentsch, J., Redmond, D., Elsworth, J., Taylor, J., Youngren, K. & Roth, R. (1997) Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science, 277, 953-955.
23. Jentsch, J.D., Roth, R.H. & Taylor, J.R. (2000) Object retrieval/detour deficits in monkeys produced by prior subchronic phencyclidine administration: evidence for cognitive impulsivity. Biol. Psychiatry, 48, 415-424.
24. Jentsch, J. & Taylor, J. (2001) Impaired inhibition of conditioned responses produced by subchronic administration of phencyclidine to rats. Neuropsychopharmacology, 24, 66-74.
25. Jentsch, J.D., Taylor, J.R., Elsworth, J.D., Redmond, D.E. Jr & Roth, R.H. (1999) Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits. Neuroscience, 90, 823-832.
26. Jentsch, J., Tran, A., Taylor, J. & Roth, R. (1998) Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioral and neurochemical evidence. Psychopharmacology, 138, 89-95.
27. Konradi, C. & Heckers, S. (2001) Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol. Psychiatry, 50, 729-742.
28. Lahti, A.C., Weiler, M.A., Tamara Michaelidis, B.A., Parwani, A. & Tamminga, C.A. (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology, 25, 455-467.
29. Laurent, V. & Podherna, J. (2004) Subchronic phencyclidine treatment impairs performance of C57BL/6 mice in the attentional set-shifting task. Behav. Pharmacol., 15, 141-148.
30. Leveque, J.-C., Macias, W., Rajadhyaksha, A., Carlson, R., Barczak, A., Kang, S., Li, X.M., Coyle, J.T., Huganir, R.L., Heckers, S. & Konradi, C. (2000) Intracellular modulation of NMDA receptor function by antipsychotic drugs. J. Neurosci., 20, 4011-4020.
31. Loughney, K., Snyder, P.B., Uher, L., Rosman, G.J., Ferguson, K. & Florio, V.A. (1999) Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase. Gene, 234, 109-117.
32. Luby, E., Cohen, B., Rosenbaum, G., Gottlieb, J. & Kelley, R. (1959) Study of a new schizophrenomimetic drug - Sernyl. Arch. Neurol. Psychiatry, 81, 113-119.
33. Moy, S.S., Fernandes, A., Qian, Y., Rotella, D.J., Kostrewa, R.M. & Breese, G.R. (2004) Effect of acute and chronic olanzapine treatment on phencyclidine-induced behavioral sensitization in rats with neonatal dopamine loss. Pharmacol. Biochem. Behav., 78, 47-56.
34. Murphy E.R., Baxter, M.G. & Rodefer, J.S. (2003) The effect of PDE10A inhibition on frontal cognitive performance in a subchronic phencyclidine model of schizophrenia. Soc. Neurosci. Abstr. [Society for Neuroscience, Washington, DC. Online. Program No. 848.2 2003 Abstract Viewer/Itinerary Planner.]
35. Olney, J. & Farber, N. (1995) Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry, 52, 998-1007.
36. Pantelis, C., Barber, F.Z., Barnes, T.R., Nelson, H.E., Owen, A.M. & Robbins, T.W. (1999) Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr. Res., 37, 251-270.
37. Sams-Dodd, F. (1998) Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology, 19, 18-25.
38. Schmidt, C., Chambers, L., Chapin, D., Fox, C., Fujiwara, R., Harms, J., McCarthy, S., Murphy, E. & Siuciak, J. (2002) Effect of PDE10 inhibition on striatal cyclic nucleotide concentration. Soc. Neurosci. Abstr. [Society for Neuroscience, Washington, DC. Online. Program No. 43. 19 2002 Abstract Viewer/Itinerary Planner]
39. Seeger, T.F., Bartlett, B., Coskran, T.M., Culp, J.S., James, L.C., Krull, D.L., Lanfear, J., Ryan, A.M., Schmidt, C.J., Strick, C.A., Varghese, A.H., Williams, R.D., Wylie, P.G. & Menniti, F.S. (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res., 985, 113-126.
40. Sharma, T. & Antonova, L. (2003) Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr. Clin. North Am., 26, 25-40.
41. Sircar, R. (2003) Postnatal phencyclidine-induced deficit in adult water maze performance is associated with N-methyl-D-aspartate receptor upregulation. Int. J. Dev. Neurosci., 21, 159-167.
42. Smith, W.S., Dowd, C.F., Johnston, C., Ko, N.U., DeArmond, S.J., Dillon, W.P., Setty, D., Lawton, M.T., Young, W.L., Higashida, R.T. & Halbach, V.V. (2004) Neurotoxicity of intra-arterial papaverine preserved with chlorobutanol used for the treatment of cerebral vasospasm after aneurismal subarachnoid hemorrhage. Stroke, 35, 2518-2522.
43. Soderling, S., Bayuga, S. & Beavo, J. (1999) Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc. Natl Acad. Sci. USA, 96, 7071-7076.
44. Soderling, S. & Beavo, J. (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr. Opin. Cell. Biol., 12, 174-179.
45. Storch, A., Ott, S., Hwang, Y.-I., Ortmann, R., Hein, A., Frenzel, S., Matsubara, K., Ohta, S., Wolf, H.-U. & Schwarz, J. (2002) Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter. Biochem. Pharmacol., 63, 909-920.
46. Turgeon, S.M., Auerbach, E.A. & Heller, M.A. (1998) The delayed effects of phencyclidine (PCP) disrupt latent inhibition in a conditioned taste aversion paradigm. Pharmacol. Biochem. Behav., 60, 553-558.
47. Wood, E.R., Dudchenko, P.A. & Eichenbaum, H. (1999) The global record of memory in hippocampal neuronal activity. Nature, 397, 613-616.
48. Zhang, H.T., Zhao, Y., Huang, Y., Dorairaj, N.R., Chandler, L.J. & O'Donnell, J.M. (2004) Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Neuropsychopharmacology, 29, 1432-1439.